Evid Based Med 18:69-70 doi:10.1136/eb-2012-100877
  • Therapeutics
  • Randomised controlled trial

Thromboprophylaxis in heart failure patients with sinus rhythm: aspirin and warfarin lead to similar cardiovascular outcomes

  1. Haqeel A Jamil
  1. Division of Cardiovascular and Diabetes Research, University of Leeds, Leeds, West Yorkshire, UK
  1. Correspondence to: Klaus K A Witte Division of Cardiovascular and Diabetes Research, LIGHT laboratories, University of Leeds, Leeds, West Yorkshire LS2 9JT, UK; k.k.witte{at}

Commentary on:


Chronic heart failure (CHF) is common, affecting 1–2% of the population and 10% of people >70 years. Patients with CHF have an increased risk of thromboembolism. Those with atrial fibrillation (AF) should receive warfarin but whether CHF patients with sinus rhythm (SR), whose risk is 1.5–3.5%,1 should receive thromboprophylaxis is unclear.

Previous studies, Warfarin/Aspirin Study in Heart failure (warfarin, aspirin 300 mg daily, placebo),2 Heart failurE Long-term Antithrombotic Study (aspirin 325 mg daily or warfarin for patients with ischaemic heart disease (IHD) or warfarin or placebo in the non-ischaemics)3 and Warfarin and Antiplatelet Therapy in Chronic Heart failure (WATCH: warfarin, clopidogrel 75 mg daily, …

Free Sample

This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of EBM.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article